EXHIBIT B
FORM OF REGISTRATION RIGHTS AGREEMENT
REGISTRATION RIGHTS AGREEMENT
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of [●], 2024, is made and entered into by and among Bellevue Life Sciences Acquisition Corp., a Delaware corporation (the “Company”) and the undersigned purchasers of the Company’s Series A Preferred Stock (each a “Subscriber” and together with any person or entity who hereafter becomes a party to this Agreement pursuant to Section 5.2 of this Agreement, being referred to herein as a “Holder” and collectively as the “Holders”).
RECITALS
WHEREAS, the Company and each Subscriber have entered into that certain Securities Subscription Agreement (the “Subscription Agreement”), pursuant to which upon closing of the Subscription Agreement each Subscriber shall purchase from Company shares of the Company’s Series A Preferred Stock, par value $0.0001 per share (the “Series A Preferred Stock”) (the “Transaction”); and
WHEREAS, in order to induce each Subscriber to enter into a Subscription Agreement, the Company has agreed to provide certain registration rights under the Securities Act of 1933, as amended from time to time (the “Securities Act”), with respect to the shares of Common Stock issuable upon conversion of the Series A Preferred Stock issued to the Holders.
NOW, THEREFORE, in consideration of the representations, covenants and agreements contained herein, and certain other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, hereby agree as follows:
ARTICLE 1
DEFINITIONS
1.1 Definitions. The terms defined in this Article 1 shall, for all purposes of this Agreement, have the respective meanings set forth below:
(a) “Adverse Disclosure” means any public disclosure of material non-public information, which disclosure, in the good faith judgment of the Chief Executive Officer or principal financial officer of the Company, after consultation with counsel to the Company, (i) would be required to be made in any Registration Statement or Prospectus in order for the applicable Registration Statement or Prospectus not to contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements contained therein (in the case of any prospectus and any preliminary prospectus, in the light of the circumstances under which they were made) not misleading, (ii) would not be required to be made at such time if the Registration Statement were not being filed, and (iii) the Company has a bona fide business purpose for not making such information public.
(b) “Agreement” has the meaning given in the Preamble.
(c) “Subscription Agreement” has the meaning given in the Recitals hereto.
(d) “Board” means the Board of Directors of the Company.
(e) “Commission” means the U.S. Securities and Exchange Commission.
(f) “Company” has the meaning given in the Preamble.
(g) “Common Stock” means the shares of Common Stock of the Company.
(h) “Conversion Shares” means the shares of Common Stock issuable upon conversion of the Series A Preferred Stock issued to the Holders.
(i) “Demand Registration” has the meaning given in Section 2.1(a).
(j) “Demanding Holder” has the meaning given in Section 2.1(a).
(k) “Exchange Act” means the Securities Exchange Act of 1934, as it may be amended from time to time.